VOR
What one share of Vor Biopharma holds
Biological Products, (No Diagnostic Substances)
Vor Biopharma, Inc. ("Vor Bio") is a clinical-stage biopharmaceutical company focused on developing a novel therapy in the treatment of autoimmune diseases. In June 2025, we in-licensed telitacicept from RemeGen Co., Ltd.
Vor Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $20.19 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$4.53 |
| Cash and investments | $8.56 |
| Book value | −$3.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$41.95 | $2.33 | −$43.69 | — | $116.35 |
| 2022 | — | −$46.57 | $4.28 | −$47.33 | — | $75.95 |
| 2023 | — | −$35.08 | $0.32 | −$30.17 | — | $44.40 |
| 2024 | — | −$34.03 | $0.07 | −$29.08 | — | $15.49 |
| 2025 | — | −$70.50 | $0.10 | −$14.55 | — | −$4.24 |